Zentalis Pharmaceuticals Llc (ZNTL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $167.05M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zentalis Pharmaceuticals Llc (ZNTL) Financials: Revenue, Profit and Cash Flow
Zentalis Pharmaceuticals Llc reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$137.06M, operating cash flow was -$125.25M and free cash flow was -$125.25M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$28.82M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $152.81M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2024 | $67.42M | N/A | 100.0% | -283.6% | -246.0% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2018 | $14.00K | N/A | 100.0% | -169878.6% | -150478.6% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.42M | $0 | $0 | $0 | $0 | $0 | $14.00K |
| Gross profit | $0 | $67.42M | $0 | $0 | $0 | $0 | $0 | $14.00K |
| Research and development | $107.30M | $167.77M | $235.16M | $172.73M | $175.60M | $84.90M | $38.39M | $18.92M |
| Operating income | -$152.81M | -$191.19M | -$299.51M | -$227.29M | -$216.54M | -$118.79M | -$46.84M | -$23.78M |
| Net income | -$137.06M | -$165.87M | -$292.31M | -$237.11M | -$166.09M | -$118.55M | -$46.38M | -$21.07M |
| EBITDA | -$138.64M | -$172.40M | -$288.66M | -$223.60M | -$214.69M | -$117.39M | -$46.25M | -$23.73M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $26.86M | $0 | $0 | $40.56M | $2.10M |
| Gross profit | $0 | $0 | $0 | -$157.00K | $0 | $0 | $0 | $26.86M | $0 | $0 | $40.56M | $1.77M |
| Operating income | -$31.15M | -$44.39M | -$37.85M | -$37.39M | -$33.73M | -$36.06M | -$45.62M | -$49.85M | -$51.43M | -$65.15M | -$24.77M | -$67.92M |
| Net income | -$28.82M | -$42.29M | -$35.35M | -$35.22M | -$26.69M | -$26.87M | -$48.28M | -$47.47M | -$40.16M | -$88.28M | $10.04M | -$60.94M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $3.87M by $32.12M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $288.97M | $430.34M | $551.69M | $539.31M | $454.51M | $365.56M | $87.48M | $41.00M |
| Current assets | $253.19M | $386.07M | $496.72M | $451.93M | $350.77M | $345.10M | $68.89M | $26.68M |
| Cash and equivalents | $35.99M | $33.90M | $28.04M | $43.07M | $59.71M | $54.95M | $67.25M | $25.15M |
| Total liabilities | $72.76M | $93.15M | $114.30M | $105.29M | $90.03M | $32.18M | $19.06M | $8.69M |
| Short-term debt | $3.87M | $3.07M | $2.62M | $2.16M | $1.45M | $902.00K | $781.00K | N/A |
| Shareholder equity | $216.20M | $337.19M | $437.28M | $433.80M | $363.95M | $308.58M | -$80.11M | $24.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $270.19M | $215.33M | $253.07M | $288.97M | $327.25M | $351.71M | $384.02M | $430.34M | $450.66M | $491.68M | $557.48M | $562.03M |
| Total liabilities | $65.31M | $71.68M | $70.39M | $72.76M | $74.38M | $77.21M | $88.64M | $93.15M | $96.33M | $109.10M | $98.71M | $124.64M |
| Cash and equivalents | $24.03M | $24.78M | $31.93M | $35.99M | $39.07M | $37.60M | $41.93M | $33.90M | $41.32M | $36.98M | $37.62M | $28.04M |
| Shareholder equity | $204.89M | $143.65M | $182.68M | $216.20M | $252.87M | $274.50M | $295.38M | $337.19M | $354.33M | $382.58M | $458.77M | $437.28M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$125.25M | -$170.86M | -$207.82M | -$163.75M | -$154.09M | -$86.83M | -$39.14M | -$24.25M |
| Capital expenditures | $0 | $221.00K | $583.00K | $2.55M | $6.11M | $758.00K | $352.00K | $227.00K |
| Free cash flow | -$125.25M | -$171.08M | -$208.41M | -$166.30M | -$160.20M | -$87.58M | -$39.49M | -$24.48M |
| Share repurchases | $9.98M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $131.62M | $176.56M | -$44.46M | -$114.18M | -$18.11M | -$284.83M | -$352.00K | -$227.00K |
| Financing cash flow | -$4.28M | $108.00K | $237.30M | $261.04M | $178.52M | $360.44M | $81.83M | $9.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.71M | -$37.24M | -$32.96M | -$30.94M | -$26.96M | -$34.71M | -$32.64M | -$39.70M | -$44.05M | -$35.14M | -$51.97M | -$40.60M |
| Capital expenditures | N/A | N/A | $34.00K | $0 | $0 | $0 | $0 | $0 | $0 | $181.00K | $40.00K | $173.00K |
| Free cash flow | N/A | N/A | -$32.99M | -$30.94M | -$26.96M | -$34.71M | -$32.64M | -$39.70M | -$44.05M | -$35.32M | -$52.01M | -$40.77M |
Frequently Asked Questions About ZNTL
What is Zentalis Pharmaceuticals Llc's annual revenue?
Zentalis Pharmaceuticals Llc reported revenue of $0 for the fiscal year ended Dec 31, 2025.
How fast is Zentalis Pharmaceuticals Llc's revenue growing?
Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Zentalis Pharmaceuticals Llc profitable?
No. Zentalis Pharmaceuticals Llc reported net income of -$137.06M for the fiscal year ended Dec 31, 2025.
How much free cash flow does ZNTL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$125.25M minus capital expenditures of $0 produced free cash flow of -$125.25M.
How much debt does Zentalis Pharmaceuticals Llc have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $3.87M and cash and equivalents of $35.99M.
ZNTL pages: Overview, Earnings, Forecast, Financials, Competitors